Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
RESEARCH TOOLSreports
Total Valuation
Telix Pharmaceuticals Ltd. has a market cap or net worth of $8.68B. The enterprise value is AU$6.22B.
Market Cap$8.68B
Enterprise ValueAU$6.22B
Share Statistics
Telix Pharmaceuticals Ltd. has 337,878,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding337,878,500
Owned by Insiders6.65%
Owned by Institutions―
Financial Efficiency
Telix Pharmaceuticals Ltd.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee1.20M
Profits Per Employee12.56K
Employee Count415
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Telix Pharmaceuticals Ltd. is ―. Telix Pharmaceuticals Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio20.69
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Telix Pharmaceuticals Ltd. had revenue of 496.66M and earned 5.21M in profits. Earnings per share was 0.02.
Revenue496.66M
Gross Profit308.50M
Operating Income51.89M
Pretax Income3.09M
Net Income5.21M
EBITDA22.97M
Earnings Per Share (EPS)0.02
Cash Flow
In the last 12 months, operating cash flow was 44.23M and capital expenditures -21.48M, giving a free cash flow of 22.75M billion.
Operating Cash Flow44.23M
Free Cash Flow22.75M
Free Cash Flow per Share0.07
Dividends & Yields
Telix Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.24
52-Week Price Change69.22%
50-Day Moving Average27.31
200-Day Moving Average23.29
Relative Strength Index (RSI)42.63
Average Volume (3m)1.67M
Important Dates
Telix Pharmaceuticals Ltd. upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.
Last Earnings DateFeb 20, 2025
Next Earnings DateAug 21, 2025
Ex-Dividend Date―
Financial Position
Telix Pharmaceuticals Ltd. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Telix Pharmaceuticals Ltd. has paid -2.12M in taxes.
Income Tax-2.12M
Effective Tax Rate―
Enterprise Valuation
Telix Pharmaceuticals Ltd. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Telix Pharmaceuticals Ltd. has $118.84M in cash and marketable securities with AU$1.73M in debt, giving a net cash position of -$96.69M billion.
Cash & Marketable Securities$118.84M
Total DebtAU$1.73M
Net Cash-$96.69M
Net Cash Per Share-$0.29
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Telix Pharmaceuticals Ltd. is $34.02, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.02
Price Target Upside35.11% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast55.85%
EPS Growth Forecast893.42%